A Study of CFI-400945 Fumarate in Patients With Advanced Cancer

Inclusion Criteria

• •Have histologic or cytological proof of advanced cancer that has progressed and for which there is no further standard anticancer therapy available in the opinion of the investigator.
• •Patients must have measurable disease as per RECIST v1.1
• •Are 18 years of age or older.
• •Have clinically acceptable laboratory screening results within certain limits
• •Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• •Able to swallow oral medications.
• •Have a life expectancy greater than 3 months.
• •Women and men of child producing potential must agree to use highly effective means of contraception during study participation, and for at least 30 days after the last administration of study medication.
• •Negative serum pregnancy test with 72 hours prior to start of study drug
• •Have the ability to understand the requirements of the study, provide written informed consent which includes authorization for release of protected health information, abide by the study restrictions, and agree to return for the required assessments.
• •Patients being treated with full dose warfarin are excluded. Patients with history of deep vein thrombosis or pulmonary embolus who are being treated with therapeutic doses of low molecular weight heparin or prophylactic dose anticoagulants may be enrolled.
• •Patients being treated with certain drugs not acceptable while receiving CFI-400945 fumarate.